Director_Research_Position_Overview

…research, bringing together best-in-class researchers, biotech companies, and patients to find treatments for CMT. The Director of Research will work closely with the Chief Executive Officer and STAR Advisory Board…

TMJulia_21

…to Accelerate Research (CMTA- STAR), our initiative which is striving to find effective treatments for CMT, we are also doing everything we can at the CMTA to ensure a brighter…

CMTA_2019-2020_Audited_Financial_Statements

…and supports research into the cause, treatment and cure of CMT disorders. The Association also facilitates education and support for persons affected by CMT disorders. (2) SUMMARY OF SIGNIFICANT ACCOUNTING…

Media_Contact_Form

…can be identified for early treatment. Charcot-Marie-Tooth is a progressive disorder of the peripheral nerves that causes people to lose the normal use of their feet and legs. Symptoms include:…

About the CMTA

…development treatments and a cure for CMT. • Because of the success of STAR, the CMTA has more than 50 active research projects with the best scientists from around the…
…employees, directors, officers, and other stakeholders of the organization, on a confidential and anonymous basis.  The receipt, retention, and treatment of complaints received by the organization regarding accounting, internal…

CMTA Whistleblower Policy

…employees, directors, officers, and other stakeholders of the organization, on a confidential and anonymous basis.  The receipt, retention, and treatment of complaints received by the organization regarding accounting, internal…

Taysha Letter to the GAN Community – 9.19.2023

treatment of giant axonal neuropathy (GAN). This decision follows the receipt of feedback from the United States (U.S.) Food and Drug Administration (FDA) regarding a registrational path for TSHA-120. FDA…

GAN Community Letter 31JAN2022 Final

treatment of giant axonal neuropathy (GAN). The trial is being conducted by the National Institute of Neurological Disorders and Stroke (NINDS) division of the National Institutes of Health (NIH). This…

CMTA PITCHBOOK 6_singles

…in the works, including testing axon-sparing strategies involving inhibition of SARM1. Work on biomarkers, which indicate if a particular treatment is effective, is underway in CMT subtypes 1A, 1X, 2A…